Antibody Humanization
Delivering Humanized Antibodies for safer Drugs
YUMAB® discovery platform generates fully human antibodies closest to natural germline among those on the market. For non-human antibodies, YUMAB provides optimized bioinformatic humanization solutions to generate humanized antibody variants mimicking sequence characteristics close to fully human antibodies.
All antibody variants are engineered to preserve the original binding affinity and specificity of the non-human antibodies while ensuring low immunogenicity and high sequence stability, making them ideally suited for clinical development. Combined with advanced in silico liability analysis and engineering tools, YUMAB delivers optimized candidates that meet the highest standards of efficacy, safety, and manufacturability.
Yumab´s Humanization Approach for fast Conversion from Animal to Human
At YUMAB, we have established a streamlined five-step workflow that transforms non-human antibodies into humanized clinical candidates. Our process integrates advanced bioinformatics, rational human framework selection, CDR grafting, and structure-guided engineering to maintain affinity, stability, and developability. Comprehensive functional and biophysical testing ensures that each variant meets the highest standards for safety, efficacy, and manufacturability. The result is a robust, humanized lead candidate optimized for successful preclinical and clinical development.
AI-assisted identification of human acceptor frame work for optimal structure homology
Grafting of non-human CDR onto human acceptor framework
Structure guided backmutation of crucial aminoacid residues essential for folding and function
Generation and production of several VH and VL variant combinations to identify the humanized antibody with optimal function, stability, and expression
